Advent Technologies (ADN) Q2 2025 earnings summary

Executive summary

• Revenue for Q2 2025 was $0.1M, down 85% year-over-year, with a net loss of $3.8M from continuing operations and $1.1M from discontinued operations.

• Significant cost increases, legal settlements, and asset write-offs contributed to a working capital deficit of $27.8M as of June 30, 2025.

• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses, overdue obligations, and insufficient cash.

• Major developments include a €34.5M EU grant for the RHyno Project, a new license agreement for Ion Pair technology, and the bankruptcy of Advent Technologies A/S.

Financial highlights

• Q2 2025 revenue fell to $0.1M from $0.7M in Q2 2024; six-month revenue dropped to $0.2M from $3.4M year-over-year.

• Net loss from continuing operations was $3.8M for Q2 2025, improved from $10.2M in Q2 2024; six-month net loss was $7.1M, down from $19.6M.

• Gross loss for Q2 2025 was $0.3M, compared to a gross profit of $0.6M in Q2 2024.

• Operating loss for Q2 2025 was $2.9M, versus operating income of $2.7M in Q2 2024.

• Adjusted EBITDA for Q2 2025 was $(3.8)M, compared to $(10.2)M in Q2 2024.

Outlook and guidance

• Management expects increased demand for fuel cell systems and MEAs as production scales, but revenue recognition is delayed due to contract liabilities.

• The company is pursuing additional fundraising and cost reductions but warns of potential insolvency if funding is not secured soon.